Current Report Filing (8-k)
January 24 2023 - 8:46AM
Edgar (US Regulatory)
false
0001213809
0001213809
2023-01-24
2023-01-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 24, 2023
Dyadic International, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
|
000-55264
(Commission File Number)
|
45-0486747
(I.R.S. Employer Identification Number)
|
140 Intracoastal Pointe Drive, Suite 404
Jupiter, FL 33477
|
(Address of principal executive offices and zip code)
|
(561) 743-8333
|
(Registrant’s telephone number, including area code)
|
N/A
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Securities registered pursuant to Section 12(b) of the Act
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
DYAI
|
The NASDAQ Stock Market LLC
|
Item 8.01 Other Events
On January 24, 2023, Dyadic International, Inc. (“Dyadic” or the “Company”) issued a press release announcing that it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference, other than the fourth paragraph of the press release.
Item 9.01 Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
The following exhibit is being filed herein:
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1 |
|
Press Release Dated January 24, 2023 |
104 |
|
Cover page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 24, 2023
Dyadic International, Inc.
|
|
|
By:
|
/s/ Mark A. Emalfarb
|
Name:
|
Mark A. Emalfarb
|
Title:
|
Chief Executive Officer
|
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024